Crohn DiseasePhase 2/3ICONIC-CDNCT07196722
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2/3 study testing Icotrokinra in people with Crohn Disease, run by Janssen Research & Development, LLC at 395 sites in 28 countries.
Trial summary
The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Crohn Disease
- What is being tested?
- Icotrokinra
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,092 participants
- Where
- 395 sitesin 28 countries
- Study dates
- 3 Oct 2025to 6 Oct 2032
- Phase
- Phase 2/3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of CD established at least 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of CD
- Moderately to severely active CD based on CDAI criteria, defined as baseline (Week I-0) CDAI score >=220 but <=450 and either mean daily SF count >=4, or mean daily AP score >=2
- Moderately to severely active CD based on SES-CD criteria assessed by baseline (Week I-0) endoscopic evidence of active ileal and/or colonic CD as assessed during central review of the screening video ileocolonoscopy defined as a SES-CD >= 6 for participants with colonic or ileocolonic disease, and SES-CD >= 4 for participants with isolated ileal disease, based on the presence of ulceration in any 1 of the 5 ileocolonic segments
- A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (beta-hCG) at screening and a negative urine pregnancy test at Week I-0 prior to administration of study intervention and agree to further pregnancy tests
- Demonstrated an inadequate response to, or failure to tolerate conventional therapy but naïve to advanced therapies (advanced drug therapy [ADT]-naïve) or inadequate response to (that is, primary or secondary nonresponse) or failure to tolerate advanced therapy defined as biologics and/or advanced oral agents for the treatment of CD- (ADT-inadequate responder [IR]) as defined in the protocol
Who cannot join
- Has complications of CD, such as symptomatic strictures or stenoses, short gut syndrome, or any other manifestation, that may require surgery while enrolled in the study and/or could impair the use of instruments (such as CDAI) to assess response to study intervention
- Presence of a stoma or ostomy
- Participants with presence of active fistulas may be included if there is no surgery needed
- Colonic resection within 24 weeks before baseline or any other major surgery performed within 12 weeks before baseline
- Presence on screening colonoscopy of adenomatous colon polyps outside of an area of known colitis not removed before randomization
Trial locations and contacts
395 sites in 28 countries. Contact the study team or a site near you to ask about taking part.
395 sites in 28 countries
United States64 sites, 57 recruiting
- Recruiting
Clinnova Research
Anaheim, California, 92805
- Recruiting
Emory University
Atlanta, Georgia, 30322
- Recruiting
Atlanta Gastroenterology Associates
Atlanta, Georgia, 30342
- Recruiting
Children's Center for Digestive Health Care
Atlanta, Georgia, 30342
- Recruiting
The University of Texas at Austin
Austin, Texas, 78712
- Completed
Alliance Research Institute, LLC - Canoga Park
Canoga Park, California, 91304
- Recruiting
Westchester Putnam Gastroenterology
Carmel, New York, 10512
- Recruiting
DFW Clinical Trials
Carrollton, Texas, 75010
- Recruiting
AZ Gastro Care
Chandler, Arizona, 85206
- Recruiting
University of North Carolina
Chapel Hill, North Carolina, 27599
- Recruiting
Medical University of South Carolina
Charleston, South Carolina, 29425
- Recruiting
Atrium Health
Charlotte, North Carolina, 28204
- Recruiting
Gastroenterology Associates of Tidewater
Chesapeake, Virginia, 23320
- Recruiting
Chevy Chase Clinical Research
Chevy Chase, Maryland, 20815
- Recruiting
Peak Gastroenterology Associates
Colorado Springs, Colorado, 80907
- Recruiting
Southern California Research Center
Coronado, California, 92118
- Recruiting
Tri-State Gastroenterology Assoc
Crestview Hills, Kentucky, 41017
- Recruiting
American Institute of Research
Cutler Bay, Florida, 33157
- Recruiting
Baylor University Medical Center
Dallas, Texas, 75246
- Recruiting
UT Southwestern Medical Center
Dallas, Texas, 75390
- Completed
Nuvance Health Danbury Hospital
Danbury, Connecticut, 06810
- Recruiting
Woodholme Gastroenterology Associates
Glen Burnie, Maryland, 21061
- Recruiting
Susquehanna Research Group
Harrisburg, Pennsylvania, 17110-3673
- Recruiting
Penn State Milton S Hershey Medical Ctr
Hershey, Pennsylvania, 17033
- Recruiting
Victorium Clinical Research
Houston, Texas, 77024
- Recruiting
IU Health University Hospital
Indianapolis, Indiana, 46202
- Recruiting
Nature Coast Clinical Research
Inverness, Florida, 34452
- Completed
Green Leaf Clinical Trials
Jacksonville, Florida, 32258
- Recruiting
Gastroenterology Clinic of Acadiana
Lafayette, Louisiana, 70503
- Recruiting
Florida Research Center Inc.
Lakewood Rch, Florida, 34211
- Recruiting
Om Research, LLC 1
Lancaster, California, 93534
- Recruiting
Research Solutions of Arizona
Litchfield Park, Arizona, 85340
- Recruiting
TLC Clinical Research Inc
Los Angeles, California, 90048
- Recruiting
GastroIntestinal Bioscience
Los Angeles, California, 90067
- Recruiting
University of Louisville - MedCenter One
Louisville, Kentucky, 40202
- Recruiting
Blue Ridge Medical Research
Lynchburg, Virginia, 24502
- Recruiting
Gastroenterolgy Associates of Central GA
Macon, Georgia, 31201
- Recruiting
Sanchez Clinical Research, Inc
Miami, Florida, 33157-6575
- Recruiting
Medical College Of Wisconsin
Milwaukee, Wisconsin, 53226
- Recruiting
Inflammatory Bowel Disease Center at NYU Langone
New York, New York, 10016
- Completed
Manhattan Clinical Research LLC
New York, New York, 10016
- Recruiting
Weill Cornell Medical College
New York, New York, 10065
- Recruiting
Lenox Hill Hospital
New York, New York, 10075
- Recruiting
New York Gastroenterology Associates
New York, New York, 10075
- Recruiting
Hoag Memorial Hospital
Newport Beach, California, 92658
- Completed
Digestive Disease Specialists Inc
Oklahoma City, Oklahoma, 73114
- Recruiting
Om Research, LLC 2
Oxnard, California, 93030
- Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
- Recruiting
Jefferson Digestive Health Institute
Philadelphia, Pennsylvania, 19107
- Recruiting
The Oregon Clinic
Portland, Oregon, 97220-9428
- Recruiting
University Gastroenterology
Providence, Rhode Island, 02905
- Recruiting
Mayo Clinic 1
Rochester, Minnesota, 55905
- Completed
Digestive Disease Associates
Rock Hill, South Carolina, 29732
- Recruiting
Southern Star Research Institute, LLC
San Antonio, Texas, 78229
- Completed
Clinical Applications Laboratories, Inc
San Diego, California, 92103
- Recruiting
Medical Associates Research Group, Inc.
San Diego, California, 92123
- Recruiting
University of California San Francisco
San Francisco, California, 94115
- Recruiting
Mayo Clinic
Scottsdale, Arizona, 85259
- Recruiting
GI Alliance Southlake
Southlake, Texas, 76092
- Recruiting
GI Alliance Tacoma
Tacoma, Washington, 98405
- Recruiting
GCP Clinical Research
Tampa, Florida, 33609
- Recruiting
Tyler Research Institute, LLC
Tyler, Texas, 75701
- Recruiting
Delta Research Partners, LLC
West Monroe, Louisiana, 71291
- Recruiting
Kansas Gastroenterology, LLC
Wichita, Kansas, 67226
China35 sites, 35 recruiting
- Recruiting
Capital Medical University, Beijing Friendship Hospital
Beijing, 100050
- Recruiting
Xiangya Hospital Central South University
Changsha, 410008
- Recruiting
The second Xiangya Hospital of Central South University
Changsha, 410011
- Recruiting
Changzhou No 2 Peoples Hospital
Changzhou, 213003
- Recruiting
West China Hospital Si Chuan University
Chengdu, 610041
- Recruiting
Chongqing General Hospital
Chongqing, 400014
- Recruiting
The First People's Hospital of Foshan
Foshan, 528000
- Recruiting
The First Affiliated Hospital of Fujian Medical University
Fuzhou, 350004
- Recruiting
The First Affiliated Hospital Sun Yat sen University
Guangzhou, 510080
- Recruiting
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, 510261
- Recruiting
The Sixth Affiliated Hospital Sun Yat sen University
Guangzhou, 510655
- Recruiting
Affiliated Hospital of Hainan Medical University
Haikou, 570102
- Recruiting
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
Hangzhou, 310016
- Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, 230022
- Recruiting
Huizhou Central People's Hospital
Huizhou, 516001
- Recruiting
Jinhua municipal central hospital
Jinhua, 321000
- Recruiting
Lanzhou University Second Hospital
Lanzhou, 730030
- Recruiting
The first affiliated hospital of Henan University of science and technology
Luoyang, 471003
- Recruiting
The affiliated hospital of Southwest Medical University
Luzhou, 646000
- Recruiting
Zhongda Hospital Southeast University
Nanjing, 210000
- Recruiting
Jiangsu Province Hospital of Traditional Chinese Medicine
Nanjing, 210004
- Recruiting
The First Affiliated Hospital of Guangxi Medical University
Nanning, 530021
- Recruiting
Ningbo medical center lihuili hospital
Ningbo, 315000
- Recruiting
Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University
Shanghai, 200023
- Recruiting
Huashan Hospital Fudan University
Shanghai, 200040
- Recruiting
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, 200127
- Recruiting
Shengjing Hospital Of China Medical University
Shenyang, 110022
- Recruiting
Shenzhen Hospital of Southern Medical University
Shenzhen, 518101
- Recruiting
Second Affiliated Hospital of Soochow University
Suzhou, 215000
- Recruiting
The 2nd Affiliated Hospital & Yuying Children s Hospital Wenzhou Medical University
Wenzhou, 325026
- Recruiting
The Central Hospital of Wuhan
Wuhan, 430014
- Recruiting
Zhongshan Hospital, Xiamen University
Xiamen, 361004
- Recruiting
Northern Jiangsu Peoples Hospital
Yangzhou, 225001
- Recruiting
ZhuZhou Central Hospital
Zhuzhou, 412007
- Recruiting
Affiliated Hospital of Zunyi Medical University
Zunyi, 563099
Japan35 sites, 34 recruiting
- Recruiting
Juntendo University Hospital Urayasu
Chiba, 279 0021
- Recruiting
Fukui Prefectural Hospital
Fukui-shi, 910-8526
- Recruiting
Gamagori City Hospital
Gamagōri, 443-8501
- Recruiting
Hamamatsu University Hospital
Hamamatsu, 431-3192
- Recruiting
Matsuda Hospital
Hamamatsu, 432-8061
- Recruiting
National Hospital Organization Mito Medical Center
Higashiibaraki-gun, 311-3193
- Recruiting
Hiroshima University Hospital
Hiroshima, 734 8551
- Recruiting
Kagawa Prefectural Central Hospital
Kagawa, 760-8557
- Recruiting
Kagoshima IBD Gastroenterology Clinic
Kagoshima, 892-0843
- Recruiting
Matsuda Pediatrics Digestion Clinic
Kanazawa, 920 0981
- Recruiting
Kanazawa University Hospital
Kanazawa, 920 8641
- Recruiting
Tsujinaka Hospital Kashiwanoha
Kashiwa, 277-0871
- Recruiting
Saitama Medical Center
Kawagoe, 350-8550
- Recruiting
Hospital of the University of Occupational and Environmental Health
Kitakyushu, 807-8556
- Recruiting
Japanese Red Cross Kumamoto Hospital
Kumamoto, 861-8520
- Recruiting
Takano Hospital
Kumamoto, 862-0971
- Recruiting
Kurume University Hospital
Kurume, 830-0011
- Recruiting
Kyorin University Hospital
Mitaka, 181-8611
- Recruiting
Takagi Clinic
Miyagi, 981-3213
- Recruiting
Aichi Medical University Hospital
Nagakute, 480-1195
- Recruiting
Nagasaki University Hospital
Nagasaki, 852-8501
- Recruiting
Hyogo Medical University Hospital
Nishinomiya Shi, 663 8501
- Recruiting
Nakagami Hospital
Okinawa, 904-2195
- Completed
Kinshukai Infusion Clinic
Osaka, 530-0011
- Recruiting
National Hospital Organization Osaka National Hospital
Osaka, 540 0006
- Recruiting
Osaka Metropolitan University Hospital
Osaka, 545 8586
- Recruiting
Saga University Hospital
Saga, 849 0937
- Recruiting
Toho University Sakura Medical Center
Sakura, 285-0841
- Recruiting
Sapporo Tokushukai Hospital
Sapporo, 004-0041
- Recruiting
Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital
Sapporo, 060-0033
- Recruiting
Sapporo IBD Clinic
Sapporo, 064-0919
- Recruiting
Tohoku University Hospital
Sendai, 980 8574
- Recruiting
National Center for Global Health and Medicine
Shinjuku- Ku, 162-8655
- Recruiting
Tokyo Yamate Medical Center
Shinjuku-ku, 169-0073
- Recruiting
National Hospital Organization Shizuoka Medical Center
Sunto-gun, 411-8611
Poland30 sites, 30 recruiting
- Recruiting
Centrum Medyczne Medis
Bydgoszcz, 85 229
- Recruiting
NZOZ Centrum Medyczne KERmed
Bydgoszcz, 85 231
- Recruiting
Osrodek Badan Klinicznych CLINSANTE S C
Bydgoszcz, 85 794
- Recruiting
Centrum Medyczne Plejady
Krakow, 30 363
- Recruiting
Malopolskie Badania Kliniczne
Krakow, 30-002
- Recruiting
Centrum Medyczne Promed
Krakow, 31-513
- Recruiting
Uniwersytecki Szpital Kliniczny nr 4
Lublin, 20 090
- Recruiting
Medrise Sp. z o.o.
Lublin, 20 582
- Recruiting
Allmedica
Nowy Targ, 34 400
- Recruiting
Medicus Zaniewski i Bilski
Olsztyn, 10-684
- Recruiting
Twoja Przychodnia Opolskie Centrum Medyczne
Opole, 45-819
- Recruiting
Uniwersyteckie Centrum Stomatologii i Medycyny Specjalistycznej Sp z o o
Poznan, 60 354
- Recruiting
NZOZZPS Termedica Centrum Badan Kliniczych
Poznan, 60 681
- Recruiting
RiverMED
Poznan, 61-441
- Recruiting
Centrum Medyczne Medyk
Rzeszów, 35-326
- Recruiting
Endoskopia Sp z o.o.
Sopot, 81 756
- Recruiting
Twoja Przychodnia - Szczecinskie Centrum Medyczne
Szczecin, 71-434
- Recruiting
Sonomed Sp. z o.o.
Szczecin, 71-685
- Recruiting
GASTROMED Sp. z o.o.
Torun, 87 100
- Recruiting
Care Access Warszawa
Warsaw, 00 719
- Recruiting
ETG Warszawa
Warsaw, 02-677
- Recruiting
Medon Clinical Research
Warsaw, 02-679
- Recruiting
WSD MEDI Clinical Sp. z o. o.
Warsaw, 02-786
- Recruiting
Bodyclinic Sp. z o.o. sp. k
Warsaw, 03 712
- Recruiting
Szpital Grochowski Im Dr Med Rafala Masztaka Sp Z O O
Warsaw, 04 073
- Recruiting
Medical Network WIP Warsaw IBD Point Profesor Kierkus
Warsaw, 04-501
- Recruiting
Centrum Medyczne Oporow
Wroclaw, 52 416
- Recruiting
Przychodnia Vistamed
Wroclaw, 53 149
- Recruiting
EMC Instytut Medyczny S A Penta Hospitals Przychodnie
Wroclaw, 54-239
- Recruiting
ETG Zamosc
Zamość, 22 400
Brazil26 sites, 26 recruiting
- Recruiting
Faculdade de Medicina Universidade Federal de Minas Gerais
Belo Horizonte, 30130 100
- Recruiting
UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
Botucatu, 18618-686
- Recruiting
L2IP Instituto de Pesquisas Clinicas
Brasília, 70200 730
- Recruiting
Chronos Clinica Medica Ltda
Brasília, 72145-450
- Recruiting
CDC - Centro Digestivo de Curitiba
Curitiba, 80430 180
- Recruiting
ATO Terapias
Fortaleza, 60140 025
- Recruiting
CECIP Jau - Centro de Estudos Clínicos do Interior Paulista Ltda
Jaú, 17201 130
- Recruiting
Galileo Medical Research Ltda
Juiz de Fora, 36033-318
- Recruiting
Cliged
Macaé, 27910-020
- Recruiting
Liga Norte Riograndense Contra O Cancer
Natal, 59062-000
- Recruiting
Complexo Hospitalar de Niteroi
Niterói, 24030-103
- Recruiting
Hospital De Clinicas De Porto Alegre
Porto Alegre, 90035 903
- Recruiting
Hospital Ernesto Dornelles
Porto Alegre, 90160-093
- Recruiting
Hospital Moinhos de Vento
Porto Alegre, 90560-032
- Recruiting
Platano Centro De Pesquisa Clinica LTDA
Recife, 52011 200
- Recruiting
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto
Ribeirão Preto, 14015 010
- Recruiting
Clinica Ibis Medicina Ltda
Salvador, 41820-020
- Recruiting
Pesquisare Saude
Santo André, 09080-110
- Recruiting
Irmandade da Santa Casa da Misericórdia de Santos
Santos, 11075-101
- Recruiting
Funfarme Sjrp
São José do Rio Preto, 15090-000
- Recruiting
BR Trials
São Paulo, 01236030
- Recruiting
Solare Trials
São Paulo, 01307-000
- Recruiting
Hospital Santa Catarina
São Paulo, 01310 000
- Recruiting
Hospital Das Clinicas Da Faculdade De Medicina Da USP
São Paulo, 05403-900
- Recruiting
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
São Paulo, 05651 901
- Recruiting
INTEGRAL Pesquisa e Ensino
Votuporanga, 15500-269
India19 sites, 19 recruiting
- Recruiting
Mazumdar Shaw Medical Centre - Narayana Hrudayalaya Limited
Bangalore, 560099
- Recruiting
Aster CMI Hospital
Bengaluru, 560092
- Recruiting
SUM Ultimate Medicare
Bhubaneswar, 751003
- Recruiting
Fortis Memorial Research Institute
Gurugram, 122002
- Recruiting
Asian Institute Of Gastroenterology
Hyderabad, 500032
- Recruiting
Yashoda Super Speciality Hospitals
Hyderabad, 500082
- Recruiting
S. R. Kalla Memorial General Hospital
Jaipur, 302001
- Recruiting
Lisie Hospital
Kochi, 682018
- Recruiting
Dayanand Medical College & Hospital, Tagore Nagar, Civil Lines
Ludhiana, 141001
- Recruiting
Fortis Hospital
Ludhiana, 141010
- Recruiting
P D Hinduja National Hospital and Medical Research Center
Mumbai, 400016
- Recruiting
GB Pant Institute of Post Graduate Medical Education & Research
New Delhi, 110002
- Recruiting
All India Institute of Medical Sciences
New Delhi, 110029
- Recruiting
Sir Ganga Ram Hospital
New Delhi, 110060
- Recruiting
Indraprastha Apollo Hospital
New Delhi, 1100776
- Recruiting
All India Institute of Medical Sciences
Patna, 801507
- Recruiting
Yashoda Super Speciality Hospitals 1
Secunderabad, 500003
- Recruiting
SIDS (Surat Institute of Digestive Sciences) Hospital and Research Centre
Surat, 395002
- Recruiting
Gujarat Gastro and Vascular Hospital
Surat, 395009
France14 sites, 13 recruiting
- Recruiting
Centre Hospitalier de la Cote Basque
Bayonne, 64100
- Recruiting
CHU de Clermont Ferrand - Site Estaing
Clermont-Ferrand, 63100
- Recruiting
APHP - Hopital Henri Mondor
Créteil, 94000
- Recruiting
Institut Prive MICI Clinique des Cedres
Échirolles, 38130
- Recruiting
CHU de Lille Hopital Claude Huriez
Lille, 59037
- Completed
GHI Le Raincy Montfermeil
Montfermeil, 93370
- Recruiting
CHU de Montpellier Hopital Saint Eloi
Montpellier, 34090
- Recruiting
Jules Verne Clinic
Nantes, 44300
- Recruiting
CHU de Nice Hopital de l Archet
Nice, 06202
- Recruiting
Hopital Saint-Antoine
Paris, 75012
- Recruiting
Hospices Civils de Lyon CHU Lyon Sud
Pierre-Bénite, 69495
- Recruiting
CHU Saint Etienne Hopital Nord
Saint-Priest-en-Jarez, 42270
- Recruiting
CHU Toulouse - Hopital de Rangueil
Toulouse, 31400
- Recruiting
CHRU de Nancy - Hopitaux de Brabois
Vandœuvre-lès-Nancy, 54500
Turkey (Türkiye)13 sites, 13 recruiting
- Recruiting
Hacettepe University Hospital
Ankara, 06230
- Recruiting
Gazi University Hospital
Ankara, 06560
- Recruiting
Ankara Bilkent Sehir Hastanesi
Ankara, 06800
- Recruiting
Antalya Training And Research Hospital
Antalya, 07100
- Recruiting
Uludag Universitesi Tıp Fakultesi Hastanesi
Bursa, 16059
- Recruiting
Koc University, School of Medicine, Koc University Hospital
Istanbul, 34010
- Recruiting
Bezmialem Vakif University Medical Faculty Hospital
Istanbul, 34093
- Recruiting
Istanbul University Cerrahpasa Medical Faculty
Istanbul, 34098
- Recruiting
Ege Universitesi Tip Fakultesi
Izmir, 35100
- Recruiting
Dokuz Eylul University Medical Faculty
Izmir, 35330
- Recruiting
Izmir Sehir Hastanesi
Izmir, 35540
- Recruiting
Kocaeli University Medical Faculty
Kocaeli, 41380
- Recruiting
Mersin University Medical Faculty
Mersin, 33343
Germany12 sites, 12 recruiting
- Recruiting
DRK Kliniken Berlin Westend
Berlin, 14050
- Recruiting
Medizinisches Versorgungszentrum (MVZ) Dachau
Dachau, 85221
- Recruiting
Universitaetsklinik Erlangen
Erlangen, 91054
- Recruiting
Studiengesellschaft Mitteldeutschland GmbH
Halle, 06108
- Recruiting
Medizinische Hochschule Hannover
Hanover, 30625
- Recruiting
Praxisgemeinschaft Jerichow
Jerichow, 39319
- Recruiting
Universitatsklinikum Schleswig Holstein Kiel
Kiel, 24105
- Recruiting
Eugastro GmbH
Leipzig, 04103
- Recruiting
Praxis fuer Gastroenterologie
Lübeck, 23560
- Recruiting
Staedtisches Klinikum Lueneburg
Lüneburg, 21339
- Recruiting
Universitaetsmedizin Rostock
Rostock, 18057
- Recruiting
Universitaetsklinikum Ulm
Ulm, 89081
South Korea12 sites, 12 recruiting
- Recruiting
Inje University Haeundae Paik Hospital
Busan, 48108
- Recruiting
Yeungnam University Hospital
Daegu, 42415
- Recruiting
The Catholic University of Korea Daejeon St Mary's Hospital
Daejeon, 34943
- Recruiting
Kyung Hee University Hospital
Dongdaemun-gu, 02447
- Recruiting
Seoul National University Bundang Hospital
Seongnam-si, 13620
- Recruiting
Seoul National University Hospital
Seoul, 03080
- Recruiting
Kangbuk Samsung Hospital
Seoul, 03181
- Recruiting
Severance Hospital Yonsei University Health System
Seoul, 03722
- Recruiting
Asan Medical Center
Seoul, 05505
- Recruiting
Gangnam Severance Hospital, Yonsei University Health System
Seoul, 06273
- Recruiting
Samsung Medical Center
Seoul, 06351
- Recruiting
The Catholic university of Korea, St. Vincent's Hospital
Suwon, 16247
Czechia10 sites, 10 recruiting
- Recruiting
Fakultni nemocnice Brno
Brno, 62500
- Recruiting
Vojenska nemocnice Brno
Brno, 636 00
- Recruiting
Centrum gastroenterologie a hepatologie s.r.o.
Kladno, 27280
- Recruiting
PreventaMed, s.r.o.
Olomouc, 77900
- Recruiting
Gastromedic, Ltd.
Pardubice, 530 03
- Recruiting
Fakultni nemocnice Kralovske Vinohrady
Prague, 100 00
- Recruiting
AXON Clinical s.r.o.
Prague, 140 00
- Recruiting
Clinoxus s r o
Prague, 14000
- Recruiting
Nemocnice Milosrdnych sester sv. Karla Boromejskeho v Praze
Praha 1- Mala Strana, 118 33
- Recruiting
MUDr. Michal Konecny, Ph.D. s.r.o.
Přerov, 750 02
Hungary10 sites, 10 recruiting
- Recruiting
Bekes Varmegyei KK Dr Rethy Pal Tagkorhaz
Békéscsaba, 5600
- Recruiting
Obudai Egeszsegugyi Centrum Kft
Budapest, 1036
- Recruiting
Semmelweis Egyetem 1
Budapest, 1082
- Recruiting
Semmelweis Egyetem
Budapest, 1083
- Recruiting
Semmelweis Egyetem, Belgyogyaszati es Hematologiai Klinika
Budapest, 1088
- Recruiting
Pannónia Magánorvosi Centrum Kft
Budapest, 1136
- Recruiting
Debreceni Egyetem Klinikai Kozpont
Debrecen, 4032
- Recruiting
Szegedi Tudomanyegyetem Aok Szent-Gyorgyi Albert Klinikai Kozpont
Szeged, 6725
- Recruiting
Clinfan Ltd. SMO
Szekszárd, 7100
- Recruiting
Szent Borbala Hospital Tatabanya
Tatabánya, 2800
Israel10 sites, 8 recruiting
- Recruiting
Ha'Emek Medical Center
Afula, 1834111
- Completed
Assuta MC
Ashdod, 7747629
- Completed
Shamir Medical Center Assaf Harofeh
Be’er Ya‘aqov, 70300
- Recruiting
Bnai Zion Medical Center
Haifa, 31048
- Recruiting
Rambam Medical Center
Haifa, 3109601
- Recruiting
Shaare Zedek Medical Center
Jerusalem, 9103102
- Recruiting
Galilee Medical Center
Nahariya, 22100
- Recruiting
Rabin Medical Center
Petah Tikva, 4941492
- Recruiting
Chaim Sheba Medical Center
Ramat Gan, 5262100
- Recruiting
Tel Aviv Sourasky Medical Center
Tel Aviv, 64239
Spain10 sites, 10 recruiting
- Recruiting
Hosp. Clinic de Barcelona
Barcelona, 08036
- Recruiting
Hosp. de Cabuenes
Gijón, 33394
- Recruiting
Hosp. Univ. Dr. Josep Trueta
Girona, 17007
- Recruiting
Hosp. Univ. de La Princesa
Madrid, 28006
- Recruiting
Hosp. Univ. Infanta Leonor
Madrid, 28031
- Recruiting
Hosp. Univ. 12 de Octubre
Madrid, 28041
- Recruiting
Hosp. Clinico Univ. de Santiago
Santiago de Compostela, 15706
- Recruiting
Hosp. Virgen Macarena
Seville, 41009
- Recruiting
Hosp. Clinico Univ. de Valencia
Valencia, 46010
- Recruiting
Hosp. Univ. I Politecni La Fe
Valencia, 46026
Canada9 sites, 7 recruiting
- Recruiting
Barrie GI Associates
Barrie, Ontario, L4M 7G1
- Recruiting
South Edmonton Gastroenterology Research Clinic
Edmonton, Alberta, Code: T6K
- Recruiting
Gastroenterology and Internal Medicine Research Institute (GIRI)
Edmonton, Alberta, T5R 1W2
- Recruiting
Viable Clinical Research
Kentville, Nova Scotia, B4N 0A3
- Recruiting
London Digestive Disease Institute
London, Ontario, N6K 1M6
- Recruiting
CHUM - Centre hospitalier universitaire de Montreal
Montreal, Quebec, H2X 0C1
- Completed
ABP Research Services Corp.
Oakville, Ontario, L6L 5L7
- Completed
Toronto Immune and Digestive Health Institute Inc
Toronto, Ontario, M6A 3B4
- Recruiting
GIRI Gastrointestinal Research Institute
Vancouver, British Columbia, V6Z 2K5
Greece9 sites, 9 recruiting
- Recruiting
Evangelismos S A
Athens, 106 76
- Recruiting
Hippokration Hospital
Athens, 115 27
- Recruiting
Thoracic General Hospital Of Athens I Sotiria
Athens, 11527
- Recruiting
University General Hospital Attikon General Hospital Of West Attica H Agia Varvara
Athens, 12462
- Recruiting
University General Hospital of Heraklion
Heraklion, 715 00
- Recruiting
Geniko Nosokomeio Nikaias Peiraia Ag. Panteleimon
Nikaia, 184 54
- Recruiting
Tzanio General Hospital of Piraeus
Piraeus, 185 36
- Recruiting
Theageneio Cancer Hospital
Thessaloniki, 546 39
- Recruiting
Ippokratio General Hospital Of Thessaloniki
Thessaloniki, 546 42
Italy9 sites, 9 recruiting
- Recruiting
ARNAS G Brotzu
Cagliari, 09121
- Recruiting
Fondazione IRCCS Ca Granda Ospedale Policlinico Di Milano
Milan, 20122
- Recruiting
Ospedale San Raffaele di Milano
Milan, 20132
- Recruiting
Fondazione IRCCS San Gerardo dei Tintori
Monza, 20900
- Recruiting
Ospedale Sacro Cuore Negrar-Verona
Negrar-Verona, 37024
- Recruiting
Azienda Ospedaliera San Camillo-Forlanini
Roma, 00152
- Recruiting
Fondazione Policlinico Universitario A Gemelli IRCCS
Roma, 00168
- Recruiting
Istituto Clinico Humanitas
Rozzano, 20089
- Recruiting
Azienda Ospedaliera Città della Salute e della Scienza di Torino
Torino, 10126
United Kingdom9 sites, 9 recruiting
- Recruiting
Queen Elizabeth Hospital Birmingham
Birmingham, B15 2GW
- Recruiting
Addenbrooke's Hospital
Cambridge, CB2 0QQ
- Recruiting
Glasgow Royal Infirmary
Glasgow, G31 2ER
- Recruiting
Fairfield General Hospital
Greater Manchester, BL9 7TD
- Recruiting
Whipps Cross University Hospital
London, E11 1NR
- Recruiting
Guy's Hospital
London, SE1 9RT
- Recruiting
St Georges University Hospital NHS Foundation Trust
London, SW17 0RE
- Recruiting
Whiston Hospital
Rainhill, L35 5DR
- Recruiting
Stepping Hill Hospital
Stockport, SK2 7JE
Belgium8 sites, 8 recruiting
- Recruiting
CHU Saint-Pierre
Brussels, 1000
- Recruiting
Cliniques Universitaires Saint Luc
Brussels, 1200
- Recruiting
AZ St. Lucas
Ghent, 9000
- Recruiting
Ghent University Hospital
Ghent, 9000
- Recruiting
Universitair Ziekenhuis Leuven
Leuven, 3000
- Recruiting
Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
Liège, 4000
- Recruiting
AZ Oostende
Ostend, 8400
- Recruiting
CHwapi
Tournai, 7500
Argentina7 sites, 7 recruiting
- Recruiting
GEDYT
AAI, C1425BGC
- Recruiting
Hospital Aleman
Buenos Aires, 1119
- Recruiting
Hospital Britanico de Buenos Aires
CABA, C1280AEB
- Recruiting
Clinica Universitaria Reina Fabiola
Córdoba, X5004FHP
- Recruiting
Hospital Privado de Cordoba
Córdoba, XX5016KEH
- Recruiting
Sanatorio Maipu
Maipu, M5515
- Recruiting
HIGEA
Mendoza, M5500
Australia7 sites, 7 recruiting
- Recruiting
Royal Adelaide Hospital
Adelaide, 5000
- Recruiting
Monash Health
Clayton, 3168
- Recruiting
Concord Repatriation General Hospital
Concord, 2139
- Recruiting
St Vincents Hospital Melbourne
Fitzroy, 3065
- Recruiting
Fiona Stanley Hospital
Murdoch, 6150
- Recruiting
John Hunter Hospital
New Lambton Heights, 2305
- Recruiting
Mater Hospital Brisbane
South Brisbane, 4101
Malaysia7 sites, 7 recruiting
- Recruiting
Hospital Sultanah Bahiyah
Alor Star, 05460
- Recruiting
Hospital Ampang
Ampang, 68000
- Recruiting
Hospital Sultanah Aminah
Johor Bahru, 80100
- Recruiting
Hospital Kuala Lumpur
Kuala Lumpur, 50586
- Recruiting
University Malaya Medical Centre
Kuala Lumpur, 50603
- Recruiting
Sultan Ahmad Shah Medical Centre IIUM
Kuantan, 25200
- Recruiting
Hospital Tuanku Jaafar
Seremban, 70300
Sweden7 sites, 7 recruiting
- Recruiting
Alingsas lasarett
Allingsas, 441 83
- Recruiting
Sahlgrenska University Hospital
Gothenburg, 413 45
- Recruiting
Linkoping University Hospital
Linköping, 581 85
- Recruiting
Orebro universitetssjukhus
Örebro, 703 82
- Recruiting
Ersta sjukhus
Stockholm, 116 30
- Recruiting
Karolinska Universitetssjukhuset Solna
Stockholm, 171 76
- Recruiting
Akademiska Sjukhuset
Uppsala, 751 85
Portugal6 sites, 6 recruiting
- Recruiting
Uls Braga - Hosp. Braga
Braga, 4710 243
- Recruiting
Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes
Guimarães, 4835 044
- Recruiting
Hosp. Lusiadas Lisboa
Lisbon, 1500-458
- Recruiting
Uls Santa Maria - Hosp. Santa Maria
Lisbon, 1649 028
- Recruiting
Uls Loures Odivelas - Hosp. Loures
Loures, 2674-514
- Recruiting
Uls Santo Antonio - Hosp. Santo Antonio
Porto, 4050 385
Romania6 sites, 6 recruiting
- Recruiting
S C Delta Health Care S R L
Bucharest, 014142
- Recruiting
Spitalul Clinic Colentina
Bucharest, 020125
- Recruiting
Digenio - Centrul Medical de Gastroenterologie, Hepatologie si Endoscopie Digestiva
Cluj-Napoca, 400061
- Recruiting
Institutul Regional de Gastroenterologie si Hepatologie Prof Dr Octavian Fodor
Cluj-Napoca, 400394
- Recruiting
Gastromed S R L
Constanța, 900600
- Recruiting
Spitalul Clinic Judetean de Urgenta Sibiu
Sibiu, 550245
Taiwan5 sites, 5 recruiting
- Recruiting
Changhua Christian Hospital
Changhua, 500
- Recruiting
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, 833
- Recruiting
National Taiwan University Hospital
Taipei, 100
- Recruiting
Mackay Memorial Hospital
Taipei, 104
- Recruiting
Linkou Chang Gung Memorial Hospital
Taoyuan, 333
Netherlands4 sites, 4 recruiting
- Recruiting
Vrije Universiteit Medisch Centrum
Amsterdam, 1081 HV
- Recruiting
Maastricht UMC
Maastricht, 6229 HX
- Recruiting
Radboud Umcn
Nijmegen, 6525 GA
- Recruiting
Franciscus Gasthuis & Vlietland
Rotterdam, 3045 PM
Switzerland2 sites, 2 recruiting
- Recruiting
Inselspital Universitatsspital Bern
Bern, 3010
- Recruiting
Kantonsspital Sankt Gallen
Sankt Gallen, 9007
About this study
Official title: A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
- Conditions
- Crohn Disease
- Being tested
- Icotrokinra, Placebo
- Medical subject headings
- Crohn Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IcotrokinraDrug
Also called JNJ-77242113
Icotrokinra will be administered orally, daily.
PlaceboDrug
Matching placebo will be administered orally, daily.
| Study group | Role | What they receive |
|---|---|---|
| Induction Study 1: Icotrokinra Dose 1 | Experimental | Participants will receive Icotrokinra dose 1 in Induction Study 1 up to Week 12. Subsequent treatment will be determined by the participant's response status at Week 12. Receives: Drug: Icotrokinra |
| Induction Study 1: Icotrokinra Dose 2 | Experimental | Participants will receive Icotrokinra dose 2 in Induction Study 1 up to Week 12. Subsequent treatment will be determined by the participant's response status at Week 12. Receives: Drug: Icotrokinra |
| Induction Study 1: Placebo | Placebo comparator | Participants will receive matching placebo in Induction Study 1 up to Week 12. Subsequent treatment will be determined by the participant's response status at Week 12. Receives: Drug: Placebo |
| Induction Study 2: Icotrokinra | Experimental | Participants will receive Icotrokinra at the dose regimen determined in Induction Study 1 up to Week 12. Subsequent study treatment will be determined by the participant's response status at Week 12. Receives: Drug: Icotrokinra |
| Induction Study 2: Placebo | Placebo comparator | Participants will receive matching placebo for up to Week 12. Subsequent study treatment will be determined by the participant's response status at Week 12. Receives: Drug: Placebo |
| Maintenance Study: Icotrokinra Dose 1 | Experimental | Participants who were receiving icotrokinra in either induction studies 1 or 2 and were in response at Week 12 of the induction study will be randomized to receive icotrokinra maintenance dose 1. Participants receiving Icotrokinra Dose 1 and meeting criteria for loss of response during the Maintenance Study will be eligibile for a single blinded dose adjustment to Icotrokinra Dose 2. After completion of the Maintenance Study through Week 40, eligible participants can participate in long-term extension (LTE). Receives: Drug: Icotrokinra |
| Maintenance Study: Icotrokinra Dose 2 | Experimental | Participants who were receiving icotrokinra in either induction studies 1 or 2 and were in response at Week 12 of the induction study will be randomized to receive icotrokinra maintenance dose 2. Participants who were non-responders at Week 12 of the induction studies will also receive icotrokinra maintenance dose 2 but will not be randomized. After completion of the Maintenance Study through Week 40, eligible participants can participate in LTE. Receives: Drug: Icotrokinra |
| Maintenance Study: Placebo | Placebo comparator | Participants who were receiving icotrokinra in either induction studies 1 or 2 and were in response at Week 12 will be randomized to receive placebo. Participants receiving placebo in induction studies 1 or 2 and in response at Week 12 of the induction study will continue to receive placebo during maintenance on non-randomized basis. Placebo non-responders from induction study will receive icotrokinra maintenance dose 2 on a non-randomized basis and will be assessed for response at Week 12.
Participants receiving placebo and meeting criteria for loss of response during the Maintenance Study will be eligible for a single blinded dose adjustment to icotrokinra dose 2. After completion of the Maintenance Study through Week 40, eligible participants can participate in LTE. Receives: Drug: Icotrokinra; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Induction Study 1: Number of Participants with Clinical Response at Week 12
Clinical response is defined as a greater than or equal to (>=) 100-point reduction from baseline in Crohn's Disease Activity Index (CDAI) score. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.
Measured: At Week 12
Induction Study 2: Number of Participants with Clinical Remission at Week 12 (Co-Primary Endpoint)
Clinical remission is defined as CDAI score less than (<) 150. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.
Measured: At Week 12
Induction Study 2: Number of Participants with Endoscopic Response at Week 12 (Co-Primary Endpoint)
Endoscopic response is defined as greater than (>) 50% improvement from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) score or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.
Measured: At Week 12
Maintenance Study: Number of Participants with Clinical Remission at Week 40 (Co-Primary Endpoint)
Clinical remission is defined as CDAI score < 150. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.
Measured: At Week 40
Maintenance Study: Number of Participants with Endoscopic Response at Week 40 (Co-Primary Endpoint)
Endoscopic response is defined as > 50% improvement from baseline in SES-CD score or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.
Measured: At Week 40
Secondary outcomes (24)
Induction Study 1: Number of Participants with Clinical Remission at Week 12
Clinical remission is defined as CDAI score < 150. CDAI scores ranging from 0 to approximately 600. Higher score indicates higher disease activity.
Measured: At Week 12
Induction Study 1: Number of Participants with Endoscopic Response at Week 12
Endoscopic response is defined as > 50% improvement from baseline in SES-CD score or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.
Measured: At Week 12
Induction Study 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important.
Measured: Up to 4 weeks after last dose of study drug (i.e., up to Week 16)
Induction Study 2: Number of Participants with Patient Reported Outcomes (PRO)-2 Remission at Week 12
PRO-2 remission is defined as an abdominal pain (AP) mean daily score less than or equal to (<=) 1 and stool frequency (SF) mean daily score <= 2.8, and no worsening of AP or SF from baseline.
Measured: At Week 12
Induction Study 2: Number of Participants with Clinical Response at Week 12
Clinical response is defined as a >= 100-point reduction from baseline in CDAI score.
Measured: At Week 12
Induction Study 2: Number of Participants Reporting Both Clinical Remission and Endoscopic Response at Week 12
Clinical remission is defined as CDAI score < 150. Endoscopic response is defined as > 50% improvement from baseline in SES-CD score or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. This is a composite endpoint defined to measure achievement of both clinical remission and endoscopic response at the participant level.
Measured: At Week 12
Induction Study 2: Number of Participants with Clinical Response at Week 4
Clinical response is defined as a >= 100-point reduction from baseline in CDAI score.
Measured: At Week 4
Induction Study 2: Number of Participants with Endoscopic Remission at Week 12
Endoscopic remission is defined as SES-CD <= 4 with at least a 2-point reduction from baseline and no sub score >1 in any individual component.
Measured: At Week 12
Induction Study 2: Number of Participants with Deep Remission at Week 12
Deep remission is a composite endpoint defined as achieving both clinical remission and endoscopic remission at the participant level. Clinical remission is defined as CDAI score < 150-point. Endoscopic remission is defined as SES-CD <= 4 with at least a 2-point reduction from baseline and no sub score >1 in any individual component.
Measured: At Week 12
Induction Study 2: Number of Participants with Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 12
IBDQ remission is defined as IBDQ score >= 170. IBDQ is a validated, 32-item, self-reported questionnaire for participants with inflammatory bowel disease (IBD) that will be used to evaluate the disease-specific health-related quality of life (HRQoL) across 4 dimensional scores: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.
Measured: At Week 12
Induction Study 2: Number of Participants with Fatigue Response at Week 12
Fatigue response is defined as a >= 7 point reduction in the patient reported outcomes measurement information system (PROMIS)-Fatigue Short Form 7a total score from baseline. The PROMIS fatigue SF-7a contains 7 items evaluating fatigue-related symptoms (that is, tiredness, exhaustion, mental tiredness, and lack of energy) and associated impacts on daily activities (that is, activity limitations related to work, self-care, and exercise). Item responses are rated on a five-point scale ranging from "never" to "always". Higher scores indicate more fatigue.
Measured: At Week 12
Induction Study 2: Number of Participants with Clinical Remission at Week 4
Clinical remission is defined as CDAI score< 150.
Measured: At Week 4
Induction Study 2: Number of Participants Reporting Both Histologic Remission and Endoscopic Remission at Week 12
Histologic remission is defined as a Robarts Histopathology Index score <=3, where each of the items of lamina propria neutrophils, neutrophils in epithelium, and erosions or ulcerations must be equal to 0. Endoscopic remission is defined as SES-CD <= 4 with at least a 2-point reduction from baseline and no sub score >1 in any individual component. This is a composite endpoint defined as achieving both histologic remission and endoscopic remission at the participant level.
Measured: At Week 12
Induction Study 2: Number of Participants with AEs and SAEs
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important.
Measured: Up to 4 weeks after last dose of study drug (i.e., up to Week 16)
Maintenance Study: Number of Participants with PRO-2 remission at Week 40
PRO-2 remission is defined as an abdominal pain (AP) mean daily score <= 1 and stool frequency (SF) mean daily score <= 2.8, and no worsening of AP or SF from baseline.
Measured: At Week 40
Maintenance Study: Number of Participants with Endoscopic Remission at Week 40
Endoscopic remission is defined as SES-CD <= 4 with at least a 2-point reduction from baseline and no sub score >1 in any individual component.
Measured: At Week 40
Maintenance Study: Number of Participants with 90-Day Corticosteroid-Free Clinical Remission at Week 40
90-day corticosteroid-free clinical remission is defined as the clinical remission at the visit and not receiving corticosteroids for at least 90 days prior to the visit. Clinical remission is defined as CDAI score < 150.
Measured: At Week 40
Maintenance Study: Number of Participants with Maintenance of Clinical Remission at Week 40
Participants with clinical remission at Week 40 among those with clinical remission at Week 0 of the maintenance study will be analyzed. Clinical remission is defined as CDAI score < 150.
Measured: At Week 40
Maintenance Study: Number of Participants Reporting Both Clinical Remission and Endoscopic Response at Week 40
Clinical remission is defined as CDAI score < 150. Endoscopic response is defined as > 50% improvement from baseline in SES-CD score or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. This is a composite endpoint defined to measure achievement of both clinical remission and endoscopic response at the participant level.
Measured: At Week 40
Maintenance Study: Number of Participants with Deep Remission at Week 40
Deep remission is a composite endpoint defined as achieving both clinical remission and endoscopic remission at the participant level. Clinical remission is defined as CDAI score < 150. Endoscopic remission is defined as SES-CD <= 4 with at least a 2-point reduction from baseline and no sub score >1 in any individual component.
Measured: At Week 40
Maintenance Study: Number of Participants Reporting Both Histologic Remission and Endoscopic Remission at Week 40
Histologic remission is defined as a Robarts Histopathology Index score <=3, where each of the items of lamina propria neutrophils, neutrophils in epithelium, and erosions or ulcerations must be equal to 0. Endoscopic remission is defined as SES-CD <= 4 with at least a 2-point reduction from baseline and no sub score >1 in any individual component. This is a composite endpoint defined as achieving both histologic remission and endoscopic remission at the participant level.
Measured: At Week 40
Maintenance Study: Number of Participants with IBDQ Remission at Week 40
IBDQ remission is defined as IBDQ score >= 170. IBDQ is a validated, 32-item, self-reported questionnaire for participants with IBD that will be used to evaluate the disease-specific HRQoL across 4 dimensional scores: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.
Measured: At Week 40
Maintenance Study: Number of Participants with Fatigue Response at Week 40
Fatigue response is defined as a >= 7 point reduction in the PROMIS-Fatigue Short Form 7a total score from baseline. The PROMIS fatigue SF-7a contains 7 items evaluating fatigue-related symptoms (that is, tiredness, exhaustion, mental tiredness, and lack of energy) and associated impacts on daily activities (that is, activity limitations related to work, self-care, and exercise). Item responses are rated on a five-point scale ranging from "never" to "always". Higher scores indicate more fatigue.
Measured: At Week 40
Maintenance Study : Number of Participants with AEs and SAEs
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important.
Measured: Up to 4 weeks after last dose of study drug (i.e., up to Week 44)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2025
- Study start3 Oct 2025
- Primary completion19 Sep 2028 (estimated)
- Study completion6 Oct 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Crohn DiseaseStudies of the same condition, open and under way.
- More trials run by Janssen Research & Development, LLCThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 1,092 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Janssen Research & Development, LLC Clinical Trial, Study director, Janssen Research & Development, LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07196722
- Sponsor's protocol ID
- 77242113CRD3001
- Other IDs
- 2025-521382-27-00, 2025
- Acronym
- ICONIC-CD
- Status last verified
- Nov 2026
- First submitted
- 22 Sep 2025
- Last updated
- 3 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- ClinicalTrials.gov ID
- NCT07196722
- Acronym / sponsor ID
- ICONIC-CD / 77242113CRD3001
- Conditions
- Crohn Disease
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,092 participants (estimated)
- Lead sponsor
- Janssen Research & Development, LLCIndustry (pharma, biotech, devices)
- Study start
- 3 Oct 2025 (actual)
- Primary completion
- 19 Sep 2028 (estimated)
- Study completion
- 6 Oct 2032 (estimated)
- First posted
- 29 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 8
| Arm | Type | Receives |
|---|---|---|
| Induction Study 1: Icotrokinra Dose 1 | Experimental | Drug: IcotrokinraParticipants will receive Icotrokinra dose 1 in Induction Study 1 up to Week 12. Subsequent treatment will be determined by the participant's response status at Week 12. |
| Induction Study 1: Icotrokinra Dose 2 | Experimental | Drug: IcotrokinraParticipants will receive Icotrokinra dose 2 in Induction Study 1 up to Week 12. Subsequent treatment will be determined by the participant's response status at Week 12. |
| Induction Study 1: Placebo | Placebo comparator | Drug: PlaceboParticipants will receive matching placebo in Induction Study 1 up to Week 12. Subsequent treatment will be determined by the participant's response status at Week 12. |
| Induction Study 2: Icotrokinra | Experimental | Drug: IcotrokinraParticipants will receive Icotrokinra at the dose regimen determined in Induction Study 1 up to Week 12. Subsequent study treatment will be determined by the participant's response status at Week 12. |
| Induction Study 2: Placebo | Placebo comparator | Drug: PlaceboParticipants will receive matching placebo for up to Week 12. Subsequent study treatment will be determined by the participant's response status at Week 12. |
| Maintenance Study: Icotrokinra Dose 1 | Experimental | Drug: IcotrokinraParticipants who were receiving icotrokinra in either induction studies 1 or 2 and were in response at Week 12 of the induction study will be randomized to receive icotrokinra maintenance dose 1. Participants receiving Icotrokinra Dose 1 and meeting criteria for loss of response during the Maintenance Study will be eligibile for a single blinded dose adjustment to Icotrokinra Dose 2. After completion of the Maintenance Study through Week 40, eligible participants can participate in long-term extension (LTE). |
| Maintenance Study: Icotrokinra Dose 2 | Experimental | Drug: IcotrokinraParticipants who were receiving icotrokinra in either induction studies 1 or 2 and were in response at Week 12 of the induction study will be randomized to receive icotrokinra maintenance dose 2. Participants who were non-responders at Week 12 of the induction studies will also receive icotrokinra maintenance dose 2 but will not be randomized. After completion of the Maintenance Study through Week 40, eligible participants can participate in LTE. |
| Maintenance Study: Placebo | Placebo comparator | Drug: Icotrokinra, Drug: PlaceboParticipants who were receiving icotrokinra in either induction studies 1 or 2 and were in response at Week 12 will be randomized to receive placebo. Participants receiving placebo in induction studies 1 or 2 and in response at Week 12 of the induction study will continue to receive placebo during maintenance on non-randomized basis. Placebo non-responders from induction study will receive icotrokinra maintenance dose 2 on a non-randomized basis and will be assessed for response at Week 12. Participants receiving placebo and meeting criteria for loss of response during the Maintenance Study will be eligible for a single blinded dose adjustment to icotrokinra dose 2. After completion of the Maintenance Study through Week 40, eligible participants can participate in LTE. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Diagnosis of CD established at least 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of CD
- Moderately to severely active CD based on CDAI criteria, defined as baseline (Week I-0) CDAI score >=220 but <=450 and either mean daily SF count >=4, or mean daily AP score >=2
- Moderately to severely active CD based on SES-CD criteria assessed by baseline (Week I-0) endoscopic evidence of active ileal and/or colonic CD as assessed during central review of the screening video ileocolonoscopy defined as a SES-CD >= 6 for participants with colonic or ileocolonic disease, and SES-CD >= 4 for participants with isolated ileal disease, based on the presence of ulceration in any 1 of the 5 ileocolonic segments
- A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (beta-hCG) at screening and a negative urine pregnancy test at Week I-0 prior to administration of study intervention and agree to further pregnancy tests
- Demonstrated an inadequate response to, or failure to tolerate conventional therapy but naïve to advanced therapies (advanced drug therapy [ADT]-naïve) or inadequate response to (that is, primary or secondary nonresponse) or failure to tolerate advanced therapy defined as biologics and/or advanced oral agents for the treatment of CD- (ADT-inadequate responder [IR]) as defined in the protocol
Key exclusion criteria (5 listed)
- Has complications of CD, such as symptomatic strictures or stenoses, short gut syndrome, or any other manifestation, that may require surgery while enrolled in the study and/or could impair the use of instruments (such as CDAI) to assess response to study intervention
- Presence of a stoma or ostomy
- Participants with presence of active fistulas may be included if there is no surgery needed
- Colonic resection within 24 weeks before baseline or any other major surgery performed within 12 weeks before baseline
- Presence on screening colonoscopy of adenomatous colon polyps outside of an area of known colitis not removed before randomization
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| IcotrokinraAlso: JNJ-77242113Icotrokinra will be administered orally, daily. | Drug | Induction Study 1: Icotrokinra Dose 1, Induction Study 1: Icotrokinra Dose 2, Induction Study 2: Icotrokinra, Maintenance Study: Icotrokinra Dose 1, Maintenance Study: Icotrokinra Dose 2, Maintenance Study: Placebo |
| PlaceboMatching placebo will be administered orally, daily. | Drug | Induction Study 1: Placebo, Induction Study 2: Placebo, Maintenance Study: Placebo |
Primary outcome
Induction Study 1: Number of Participants with Clinical Response at Week 12
Time frame: At Week 12
Clinical response is defined as a greater than or equal to (>=) 100-point reduction from baseline in Crohn's Disease Activity Index (CDAI) score. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.
Induction Study 2: Number of Participants with Clinical Remission at Week 12 (Co-Primary Endpoint)
Time frame: At Week 12
Clinical remission is defined as CDAI score less than (<) 150. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.
Induction Study 2: Number of Participants with Endoscopic Response at Week 12 (Co-Primary Endpoint)
Time frame: At Week 12
Endoscopic response is defined as greater than (>) 50% improvement from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) score or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.
Maintenance Study: Number of Participants with Clinical Remission at Week 40 (Co-Primary Endpoint)
Time frame: At Week 40
Clinical remission is defined as CDAI score < 150. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.
Maintenance Study: Number of Participants with Endoscopic Response at Week 40 (Co-Primary Endpoint)
Time frame: At Week 40
Endoscopic response is defined as > 50% improvement from baseline in SES-CD score or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.
24 secondary outcomes
Induction Study 1: Number of Participants with Clinical Remission at Week 12
Time frame: At Week 12
Induction Study 1: Number of Participants with Endoscopic Response at Week 12
Time frame: At Week 12
Induction Study 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Up to 4 weeks after last dose of study drug (i.e., up to Week 16)
Induction Study 2: Number of Participants with Patient Reported Outcomes (PRO)-2 Remission at Week 12
Time frame: At Week 12
Induction Study 2: Number of Participants with Clinical Response at Week 12
Time frame: At Week 12
Induction Study 2: Number of Participants Reporting Both Clinical Remission and Endoscopic Response at Week 12
Time frame: At Week 12
Induction Study 2: Number of Participants with Clinical Response at Week 4
Time frame: At Week 4
Induction Study 2: Number of Participants with Endoscopic Remission at Week 12
Time frame: At Week 12
Induction Study 2: Number of Participants with Deep Remission at Week 12
Time frame: At Week 12
Induction Study 2: Number of Participants with Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 12
Time frame: At Week 12
Induction Study 2: Number of Participants with Fatigue Response at Week 12
Time frame: At Week 12
Induction Study 2: Number of Participants with Clinical Remission at Week 4
Time frame: At Week 4
Induction Study 2: Number of Participants Reporting Both Histologic Remission and Endoscopic Remission at Week 12
Time frame: At Week 12
Induction Study 2: Number of Participants with AEs and SAEs
Time frame: Up to 4 weeks after last dose of study drug (i.e., up to Week 16)
Maintenance Study: Number of Participants with PRO-2 remission at Week 40
Time frame: At Week 40
Maintenance Study: Number of Participants with Endoscopic Remission at Week 40
Time frame: At Week 40
Maintenance Study: Number of Participants with 90-Day Corticosteroid-Free Clinical Remission at Week 40
Time frame: At Week 40
Maintenance Study: Number of Participants with Maintenance of Clinical Remission at Week 40
Time frame: At Week 40
Maintenance Study: Number of Participants Reporting Both Clinical Remission and Endoscopic Response at Week 40
Time frame: At Week 40
Maintenance Study: Number of Participants with Deep Remission at Week 40
Time frame: At Week 40
Maintenance Study: Number of Participants Reporting Both Histologic Remission and Endoscopic Remission at Week 40
Time frame: At Week 40
Maintenance Study: Number of Participants with IBDQ Remission at Week 40
Time frame: At Week 40
Maintenance Study: Number of Participants with Fatigue Response at Week 40
Time frame: At Week 40
Maintenance Study : Number of Participants with AEs and SAEs
Time frame: Up to 4 weeks after last dose of study drug (i.e., up to Week 44)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2026.
- Individual participant dataSharing planned: Yes. The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Related trials for Crohn Disease
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Enrolling by invitationPhase 4
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Janssen Research & Development, LLC Clinical Trial study director
Janssen Research & Development, LLC
395 sites in 28 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Icotrokinra in people with Crohn Disease, run by Janssen Research & Development, LLC at 395 sites in 28 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 395 sites in United States, China, Japan, Poland, Brazil and 23 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Study Contact (844-434-4210, Participate-In-This-Study1@its.jnj.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Induction Study 1: Number of Participants with Clinical Response at Week 12 (time frame: At Week 12). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.